IRIS
BLANDINI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.773
EU - Europa 2.026
AS - Asia 1.251
SA - Sud America 150
AF - Africa 28
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.718
IE - Irlanda 972
CN - Cina 803
SG - Singapore 310
FI - Finlandia 224
DE - Germania 215
UA - Ucraina 195
IT - Italia 137
BR - Brasile 133
SE - Svezia 67
GB - Regno Unito 55
CA - Canada 51
HK - Hong Kong 46
CZ - Repubblica Ceca 36
FR - Francia 35
JP - Giappone 29
BE - Belgio 23
RU - Federazione Russa 16
MU - Mauritius 14
AT - Austria 13
AU - Australia 10
TR - Turchia 9
AZ - Azerbaigian 6
NL - Olanda 6
IN - India 5
SA - Arabia Saudita 5
CH - Svizzera 4
EC - Ecuador 4
IQ - Iraq 4
LT - Lituania 4
MA - Marocco 4
PE - Perù 4
PK - Pakistan 4
PL - Polonia 4
ZA - Sudafrica 4
EG - Egitto 3
EU - Europa 3
LV - Lettonia 3
PY - Paraguay 3
AR - Argentina 2
BG - Bulgaria 2
CO - Colombia 2
CY - Cipro 2
ES - Italia 2
ID - Indonesia 2
IL - Israele 2
IS - Islanda 2
JO - Giordania 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MX - Messico 2
MY - Malesia 2
NZ - Nuova Zelanda 2
RO - Romania 2
TJ - Tagikistan 2
TN - Tunisia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BY - Bielorussia 1
CL - Cile 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
NG - Nigeria 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 7.243
Salva come PNG Salva come JPEG
Città #
Chandler 1.008
Dublin 972
Ashburn 317
Jacksonville 251
Boardman 228
Princeton 190
Lawrence 186
Nanjing 176
Medford 152
Wilmington 136
Singapore 121
Helsinki 115
Shanghai 83
Nanchang 77
Shenyang 68
Beijing 60
Changsha 54
Hebei 45
New York 45
Toronto 45
Ann Arbor 43
Chicago 42
Hong Kong 42
Jiaxing 42
Pavia 36
Tianjin 33
Brno 32
Norwalk 31
Hangzhou 28
Tokyo 27
Los Angeles 26
Milan 26
Washington 26
Brussels 23
Falkenstein 20
San Francisco 17
Nuremberg 16
Piscataway 16
São Paulo 16
Fairfield 14
Woodbridge 14
Munich 13
Des Moines 10
Philadelphia 10
Seattle 10
Dallas 9
Rome 8
Zhengzhou 8
Guangzhou 7
Mariglianella 7
Verona 7
Vienna 7
Baku 6
Jinan 6
Ningbo 6
Paris 6
Wuhan 6
Kunming 5
Newark 5
Berlin 4
Dongguan 4
Falls Church 4
Giessen 4
London 4
Santa Clara 4
Shijiazhuang 4
Southend 4
Asti 3
Belo Horizonte 3
Borås 3
Cairo 3
Canberra 3
Caruaru 3
Dearborn 3
Lima 3
Prague 3
Rio de Janeiro 3
Riyadh 3
Salvador 3
Sumaré 3
Warsaw 3
Xi'an 3
Zurich 3
Amman 2
Aracaju 2
Araçatuba 2
Asunción 2
Atlanta 2
Auburn Hills 2
Auckland 2
Bauru 2
Brasília 2
Bursa 2
Central 2
Changchun 2
Chengdu 2
Cologne 2
Colombo 2
Curitiba 2
Dalian 2
Totale 5.149
Salva come PNG Salva come JPEG
Nome #
Correlation of LTP and LTD with gene expression in the cerebellar cortex. 101
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. 95
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model 94
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 90
Immediate early genes regulation in rat cerebellar cortex during long-term synaptic plasticity induction. 81
Stress and Autonomic Nervous System 80
Alterazioni neurochimiche del sistema nervoso enterico (SNE) in un modello sperimentale di Parkinson 76
Acute Reduction of Anandamide-Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medication-Overuse Headache Subjects After Withdrawal Treatment. 75
A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. 74
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 73
Aging and dementia: markers of the hypothalamus-pituitary-adrenal axis and sympathetic activities in biological fluids 72
Long-term synaptic plasticity and related gene expression in the cerebellar cortex. 71
Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer 68
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats 67
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. 66
Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: Relevance to gastrointestinal dysfunctions in Parkinson's disease 65
The role of dopamine in the modulation of gastrointestinal motility in a rat model of Parkinson's disease 64
Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury 64
Functional changes of the basal ganglia circuitry in Parkinson's disease. 62
Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self perpetuating crosstalk? 62
Nitroglycerin-induced activation of monoaminergic trasmission in the rat 61
From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries 60
Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. 60
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 59
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 59
Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. 58
Homocysteine and Parkinson's disease: a dangerous liaison? 57
Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. 57
Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. 57
Valutazione delle catecolamine plasmatiche: influenza di fattori ambientali e delle procedure di campionamento 57
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells 57
Peripheral levels of BDNF and NGF in primary headaches 56
Modulation of noradrenergic activity by magnesium salts in panic disorder and neuronal hyperexcitability syndrome 54
Systemic administration of ephedrine induces Fos protein expression in caudate putamen and subthalamic nucleus of rats. 54
Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease 54
Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. 53
Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat 53
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 53
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 52
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. 51
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. 51
Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat 50
Free plasma catecholamine levels in healthy subjects: a basal and dynamic study 50
Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: Potential relevance to the pathophysiology of Parkinson's disease 50
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 49
Movement disorders and aging. 48
Intestinal dysmotility and enteric neurochemical changes following nigrostriatal dopaminergic denervation in the rat: relevance to the gastrointestinal dysfunction associated with Parkinson's disease 48
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease 47
In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson's disease 47
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: Potential targets for a new therapeutic approach 47
A 2A receptor antagonism and dyskinesia in parkinson's disease 47
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. 46
Effect of nitric oxide donors on the central nervous system--nitroglycerin studies in the rat. 46
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 46
Naproxen Sodium in Menstrual Migraine Prophylaxis: A Double‐Blind Placebo Controlled Study 46
Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain 45
The influence of gender in the evaluation of platelet and plasma catecholamines 45
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity 45
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease 45
Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease 45
Repurposing opportunities for Parkinson’s disease therapies 45
Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease 45
Parkinson's disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients 44
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 44
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat 43
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease 43
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease 43
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease 43
Pro-oxidant activity and methionine metabolism in chronic alcohol abusers: relationship to alcohol withdrawal and folate administration 43
Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease 43
Variabilita' delle risposte adattative a stimoli stressanti nell'uomo in rapporto all'eta'. 42
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 42
Fibroblasts from skin biopsies as a tool for biomarker discovery in Parkinson׳s disease 42
Potential therapeutic effects of polyphenols in Parkinson's disease: In vivo and in vitro pre-clinical studies 42
Assay of [3H] dihydrorotenone binding to complex I in intact human platelets 42
Cardiopressor effects of short-term treatment with cabergoline in L-Dopa stable responder parkinsonian patients: Relevance of postprandial hypotension 42
Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine 42
Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects 42
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease 42
Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease 41
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 40
Activation of brain metabolism and fos during limbic seizures: The role of Locus Coeruleus 40
A reliable indirect cell-labelling protocol for optical imaging allows ex vivo visualisation of mesenchymal stem cells after transplantation 40
Prospects of glutamate antagonists in the therapy of Parkinson's disease 40
Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease 40
Animal models of Parkinson's disease 40
Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia 39
Cerebrospinal fluid norepinephrine, 3 -methoxy 4 -hydroxyphenylglicol and neuropeptide Y levels in dementia of the Alzheimer type 38
Plasma beta-endorphin, cortisol and norepinephrine responses to physical and metabolic stressors in young and elderly humans. 38
Dopaminergic Modulation of Apoptosis in Human Peripheral Blood Mononuclear Cells: Possible Relevance for Parkinson's Disease 38
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations 38
Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia 37
The 6-hydroxydopamine model: News from the past 37
Calcium homeostasis is dysregulated in Parkinsonian patients with L-DOPA-induced dyskinesias 37
Dopamine receptor agonists for Parkinson's disease 37
Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: Implications for reparative therapy in Parkinson's disease 37
Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia 36
Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia 36
Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine 36
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 36
Totale 5.180
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.695
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.695
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020116 0 0 0 0 0 0 0 0 3 58 51 4
2020/2021506 43 34 8 38 1 47 4 69 123 77 53 9
2021/2022816 6 2 34 6 4 16 12 43 51 11 122 509
2022/20232.712 302 199 43 236 218 259 0 165 1.184 9 55 42
2023/2024969 121 146 44 56 92 250 35 56 7 27 57 78
2024/20251.243 121 215 66 80 88 152 145 176 200 0 0 0
Totale 7.448